

DAFTAR PUSTAKA

- Ashraf, M., Souka, A. & Adelman, R. J. B. J. O. O. 2016. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. 100, 1596-1604.
- Blaha, G. R., Brooks, N. O., Mackel, C. E., Pani, A., Stewart, A. P., Price, L. L., Barouch, F. C., Chang, J. & Marx, J. L. J. R. 2015. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications. 35, 577-581.
- Brownlee, M. 2005. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes*, 54, 1615-1625.
- Bucci Jr, F. A., Waterbury, L. D. & Amico, L. M. 2007. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4%(acular LS) and nepafenac 0.1%(nevanac) in patients undergoing phacoemulsification. *Am. J. Ophthalmol.*, 144, 146-147.
- Cáceres-Del-Carpio, J., Costa, R. D., Haider, A., Narayanan, R. & Kuppermann, B. D. 2016. Corticosteroids: triamcinolone, dexamethasone and fluocinolone. *Retinal Pharmacotherapeutics*. Karger Publishers.
- Cagini, C., Pellegrino, A., Cerquaglia, A., Iaccheri, B., Lupidi, M. & Fiore, T. J. C. E. R. 2020. Comparison of the effect of diclofenac 0.1% and nepafenac 0.1% on aqueous flare in patients undergoing cataract surgery: a prospective randomized study. 45, 1089-1093.
- Callanan, D. & Williams, P. 2008. Topical nepafenac in the treatment of diabetic macular edema. *Clinical Ophthalmology (Auckland, NZ)*, 2, 689.
- Capote, A. M. C., Soto, M. L., Ruiz, F. R., Peláez, E. C., Vazquez, A. G., Oftacosta, G. & Suárez, A. R. J. I. J. O. O. 2018. Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification. 11, 1210.
- Das, A., Mcguire, P. G. & Rangasamy, S. 2015. Diabetic macular edema: pathophysiology and novel therapeutic targets. *Ophthalmology*, 122, 1375-1394.
- Duong, H.-V. Q., Westfield, K. C. & Singleton, I. C. 2014. Treatment paradigm after uncomplicated cataract surgery: a prospective evaluation. *The Asia-Pacific Journal of Ophthalmology*, 3, 220-225.
- Elbendary, A. M. & Shahin, M. M. 2011. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. *Retina*, 31, 2058-2064.
- Faghihi, H., Yahyapour, H., Mahmoudzadeh, R., Faghihi, S. J. M. H., Discovery & Ophthalmology, I. I. 2017. Comparison of intravitreal bevacizumab and intravitreal diclofenac in the treatment of diabetic macular edema: a 6-month follow-up. 6, 67.
- Friedman, S. M., Almukhtar, T. H., Baker, C. W., Glassman, A. R., Elman, M. J., Bressler, N. M., Maker, M. P., Jampol, L. M., Melia, M. & Retina, D. R. C. R. N. J. 2015. Topical nepafenec in eyes with non-central diabetic macular edema. 35, 944.

- Funatsu, H., Yamashita, H., Ikeda, T., Mimura, T., Eguchi, S. & Hori, S. 2003. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. *Ophthalmology*, 110, 1690-1696.
- Gillies, M. C., Kuzniarz, M., Craig, J., Ball, M., Luo, W. & Simpson, J. M. 2005. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. *Ophthalmology*, 112, 139-143.
- Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U. & Shaw, J. E. 2014. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res. Clin. Pract.*, 103, 137-149.
- Hammes, H.-P., Welp, R., Kempe, H.-P., Wagner, C., Siegel, E., Holl, R. W., Network, D. I. G. B. C. & Mellitus, D. 2015. Risk factors for retinopathy and DME in type 2 diabetes—results from the German/Austrian DPV Database. *PLoS One*, 10, e0132492.
- Han, S. B., Yang, H. K. & Hyon, J. Y. J. C. I. I. A. 2019. Influence of diabetes mellitus on anterior segment of the eye. 14, 53.
- Heier, J. S., Awh, C. C., Busbee, B. G., Waterbury, L. D., Daniel, P., Stoller, G. L. & Cleary, T. S. 2009. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. *Retina*, 29, 1310-1313.
- Himawan, E., Ekström, P., Buzgo, M., Gaillard, P., Stefánsson, E., Marigo, V., Loftsson, T. & Paquet-Durand, F. J. D. D. T. 2019. Drug delivery to retinal photoreceptors. 24, 1637-1643.
- Hughes, P. M., Olejnik, O., Chang-Lin, J.-E. & Wilson, C. G. J. a. D. D. R. 2005. Topical and systemic drug delivery to the posterior segments. 57, 2010-2032.
- Jeon, S. & Lee, W. K. J. C. O. 2014. Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates. 8, 1479.
- Jones, J. & Francis, P. 2009. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. *Expert Opin. Pharmacother.*, 10, 2379-2385.
- Kang, H. M., Kwon, H. J., Yi, J. H., Lee, C. S. & Lee, S. C. J. a. J. O. O. 2014. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. 157, 1013-1021. e1.
- Kapin, M., Yanni, J., Brady, M., McDonough, T., Flanagan, J., Rawji, M., Dahlin, D., Sanders, M. & Gamache, D. 2003. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. *Inflammation*, 27, 281-291.
- Kida, T., Kozai, S., Takahashi, H., Isaka, M., Tokushige, H. & Sakamoto, T. J. P. O. 2014. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. 9, e96481.
- Kim, S. J., Flach, A. J. & Jampol, L. M. 2010. Nonsteroidal anti-inflammatory drugs in ophthalmology. *Surv. Ophthalmol.*, 55, 108-133.

- Lazic, R., Lukic, M., Boras, I., Draca, N., Vlastic, M., Gabric, N. & Tomic, Z. 2014. Treatment of Anti-Vascular Endothelial Growth Factor-Resistant Diabetic Macular Edema With Dexamethasone Intravitreal Implant. *Retina*, 34, 719-724.
- Li, S., Hu, A., Wang, W., Ding, X. & Lu, L. J. P. O. 2017. Combinatorial treatment with topical NSAIDs and anti-VEGF for age-related macular degeneration, a meta-analysis. 12, e0184998.
- Medić, A., Jukić, T., Matas, A., Vukojević, K., Sapunar, A. & Znaor, L. 2017. Effect of preoperative topical diclofenac on intraocular interleukin-12 concentration and macular edema after cataract surgery in patients with diabetic retinopathy: a randomized controlled trial. *Croat. Med. J.*, 58, 49-55.
- Nourinia, R., Ahmadi, H., Nekoei, E., Malekifar, P. & Tofighi, Z. J. R. 2018. Changes in central choroidal thickness after treatment of diabetic macular edema with intravitreal bevacizumab correlation with central macular thickness and best-corrected visual acuity. 38, 970-975.
- Ohira, A., Hara, K., Jóhannesson, G., Tanito, M., Ásgrímsdóttir, G. M., Lund, S. H., Loftsson, T. & Stefánsson, E. 2015. Topical dexamethasone γ -cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema. *Acta Ophthalmol. (Copenh.)*, 93, 610-615.
- Ono, Y., Aoki, S., Ohnishi, K., Yasuda, T., Kawano, K. & Tsukada, Y. 1998. Increased serum levels of advanced glycation end-products and diabetic complications. *Diabetes Res. Clin. Pract.*, 41, 131-137.
- Ophthalmology, D. R. C. R. N. J. 2007. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. 114, 525-536.
- Parravano, M., Costanzo, E. & Querques, G. J. a. D. 2020. Profile of non-responder and late responder patients treated for diabetic macular edema: systemic and ocular factors. 1-11.
- Pinna, A., Blasetti, F., Ricci, G. D. A. & Boscia, F. 2017. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. *Eur. J. Ophthalmol.*, 27, 326-330.
- Romero-Aroca, P. 2010. Targeting the pathophysiology of diabetic macular edema. *Am Diabetes Assoc.*
- Russo, A., Costagliola, C., Delcassi, L., Parmeggiani, F., Romano, M. R. & Semeraro, F. 2013. Topical nonsteroidal anti-inflammatory drugs for macular edema. *Mediators Inflamm.*, 2013.
- Schechter, B. A. & Trattler, W. 2010. Efficacy and safety of bromfenac for the treatment of corneal ulcer pain. *Adv. Ther.*, 27, 756-761.
- Sheth, J. U., Giridhar, A., Rajesh, B. & Gopalakrishnan, M. J. R. 2017. Characterization of macular choroidal thickness in ischemic and nonischemic diabetic maculopathy. 37, 522-528.
- Shiraya, T., Kure, K., Araki, F., Kato, S. & Kaiya, T. J. J. J. O. O. 2020. Correlation between anterior chamber flare changes and diabetic macular

- edema after intravitreal injection of ranibizumab and aflibercept. 64, 250-256.
- Sonoda, S., Sakamoto, T., Yamashita, T., Shirasawa, M., Otsuka, H. & Sonoda, Y. J. R. 2014. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. 34, 741-748.
- Srinivas, S., Verma, A., Nittala, M. G., Alagorie, A. R., Nassisi, M., Gasperini, J. & Sadda, S. R. J. a. J. O. O. 2020. Effect of intravitreal ranibizumab on intraretinal hard exudates in eyes with diabetic macular edema. 211, 183-190.
- Stewart, R. H., Grillone, L. R., Shiffman, M. L., Donnenfeld, E. D., Gow, J. A. & Group, B. O. S. S. 2007. The systemic safety of bromfenac ophthalmic solution 0.09%. *J. Ocul. Pharmacol. Ther.*, 23, 601-612.
- Unlu, N., Kocaoglan, H., Sayin, F., Hazirolan, D., Demircan, S., Basci, N., Acar, M. A., Demir, N. M. & Duman, S. 2010. Penetration of topically applied diclofenac and ketorolac into the aqueous humour and subretinal fluid: randomized clinical trial. *Can. J. Ophthalmol.*, 45, 610-615.
- Warboys, C. & Fraser, P. 2010. Hyperglycemia attenuates acute permeability response to advanced glycation end products in retinal microvasculature. *Microvasc. Res.*, 80, 174-176.
- Warren, K. A., Bahrani, H. & Fox, J. E. 2010. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. *Retina*, 30, 260-266.
- Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Aiello, L. P., Antoszyk, A. N., Arnold-Bush, B., Baker, C. W., Bressler, N. M. & Browning, D. J. 2015. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *The New England journal of medicine*, 372, 1193-1203.
- Yau, J. W., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A. & Grauslund, J. 2012. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*, 35, 556-564.
- Ylinen, P., Taipale, C., Lindholm, J. M., Laine, I., Holmström, E. & Tuuminen, R. 2018. Postoperative management in cataract surgery: nepafenac and preservative-free diclofenac compared. *Acta Ophthalmol. (Copenh.)*, 96, 853-859.